Clinical Trial Update: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) [Phase 3]

View source ↗

Summary

This document announces the completion of a Phase 3 safety and efficacy study evaluating TRx0237 for behavioral variant frontotemporal dementia (bvFTD) conducte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behavioral Variant Frontotemporal Dementia

Drugs mentioned

• TRx0237

Snippet

Sponsor: TauRx Therapeutics Ltd | Conditions: Behavioral Variant Frontotemporal Dementia (bvFTD) | Phase 3 | Status: COMPLETED